- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01887314
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
Multicenter, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Activity of a Ginger (Zingiber Officinale) Food Supplement in the Management of Nausea in Patients Receiving Highly Emetogenic Treatments and Standard Anti-emetogenic Therapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
This study is a randomized, double-blind, placebo controlled, multicenter study with two parallel groups of patients.
The study will be conducted in 5 Italian clinical sites and will involve 250 patients receiving at least 2 cycles of highly emetogenic treatments.
Patients will be randomly assigned to Ginger treatment or to its Placebo.
All patients will receive, at each chemotherapy cycle, the standard 5-HT3 receptor antagonist antiemetics plus dexamethasone and NK1 receptor antagonist. This will guarantee to all patients an antiemetic prophylaxis for acute and delayed nausea. No additional treatment is usually foreseen for nausea and this justifies the use of placebo in the control group.
Patients will start the study treatment on the day after chemotherapy cycle and will continue until the day of the following cycle; they will suspend the study treatment on the chemotherapy day and will start again on the next day. The choice not to treat the patients with the study product on the chemotherapy day is intended to avoid any possible interference with antiemetic therapy of the first day and chemotherapy, and to analyze the impact of Ginger in delayed phase without confounding factors in acute phase.
Main efficacy assessment of this study is:
- To evaluate the protection from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea);
Other efficacy assessments regarding nausea that will be evaluated are:
- To evaluate the severity of delayed nausea;
- To evaluate the overall duration of nausea;
- To evaluate inter cycle nausea;
- To evaluate nausea anticipatory symptoms before the 2nd cycle.
Secondary efficacy assessments of this study are:
- To evaluate protection from delayed vomiting (number of emetic episodes in delayed phase);
- To evaluate the impact of nausea/vomiting on daily life activities (FLIE30 questionnaire);
- To evaluate the use of antiemetic rescue medication;
- To evaluate the compliance to the treatment;
- To assess overall fatigue (BFI31 questionnaire).
Safety assessments of this study are:
- Number and typology of adverse events.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20133
- Istituto Nazionale dei Tumori
-
Milan, Italy, 20141
- IEO -Istituto Europeo di Oncologia-
-
Monza, Italy, 20052
- Ospedale S. Gerardo
-
Rome, Italy, 00186
- Policlinico Umberto I
-
Rome, Italy
- Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori "Regina Elena"
-
Terni, Italy, 05100
- Ospedale S. Maria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and Females aged > 18 years.
- Naïve to chemotherapy.
- Patients planned to receive at least 2 cycles of highly emetogenic treatments with cisplatin in single dose > 50 mg/m2 every 21 or 28 days.
- Willing and able to understand and sign informed consent and complete the patient diary.
Exclusion Criteria:
- Presence of brain symptomatic metastases (in case of small, asymptomatic metastases and in absence of steroids treatment, the patient is eligible).
- Scheduled to receive or having received in the past 4 weeks radiation treatment to brain, abdomen or pelvis.
- Emesis or significant nausea within 24 hours before first chemotherapy cycle.
- Known hypersensitivity reaction to Ginger or any components of the product.
- Patients with coagulopathies causing potential increase risk of bleeding.
- Patients on therapy with oral anticoagulants.
- Planned surgery procedures in the period of the study or within 2 weeks after the study conclusion.
- History of seizures.
- Active use of cannabinoids.
- Known current or past drug or alcohol abuse.
- Use of other investigational drugs within 30 days before study entry or during the study.
- Clinically significant findings on physical exam or presence of known clinically significant disease that would interfere with study evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Standardized Ginger extract soft gel capsules
Patients receive 2 soft gel capsules of Ginger extract, twice a day
|
Other Names:
|
Placebo Comparator: Placebo soft gel capsules
Patients receive 2 soft gel capsules of Placebo, twice a day
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of Ginger in protecting patients from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea)
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
The level of nausea will be assessed through a Visual Analogue Scale (VAS 0-100 mm) included in the patients' daily diary. The patients will be asked to report the maximum level of nausea experienced during each day. During each chemotherapy cycle, the nausea occurring between day 2 and day 5 will be defined as "delayed nausea", the nausea occurring between day 6 and day 19/26 will be considered as "inter-cycle nausea". The day before the next chemotherapy cycle (day 20/27), "anticipatory nausea" symptoms will be collected. |
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Protection from delayed vomiting (number of emetic episodes in delayed phase)
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Use of antiemetic rescue medication.
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Overall fatigue assessment (BFI questionnaire)
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical markers
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
On a restricted number of patients enrolled at the coordinating center, additional blood samples will be collected for IL-6, TNF-alpha, IGF-1 evaluation. The purpose of this additional research is to evaluate if the consumption of ginger can affect serum concentration of such factors. |
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
To evaluate the safety profile of the product containing Ginger extract.
Time Frame: Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Number and typology of adverse events
|
Two High Emetogenic chemotherapy cylces (41 or 55 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paolo Bossi, M.D., Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HF01-12-69 (Other Identifier: Helsinn Healthcare SA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Standardized Ginger extract
-
Emily DiMango, MDNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Antigen Laboratories, Inc.Completed
-
9305-9954 Quebec IncMcMaster UniversityWithdrawnChronic Pain | InsomniaCanada
-
Greer LaboratoriesCompletedAllergic RhinitisUnited States
-
University of MinnesotaCompleted
-
Milsing d.o.o.CompletedMild Cognitive Impairment | Cerebrovascular InsufficiencyCroatia
-
Sanni RajuOhio State UniversityCompleted
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI); National Center for Complementary and Integrative...CompletedUnspecified Adult Solid Tumor, Protocol Specific | Nausea and VomitingUnited States, Puerto Rico
-
Medika Natura Sdn BhdZach Biotech Depot Sdn BhdCompleted
-
Antigen Laboratories, Inc.WithdrawnAllergic Rhinitis